



Definitive Notice of the End Result

of the public tender offer by

CSL Behring AG, Berne, Switzerland

for all publicly held registered shares with a nominal value of CHF 0.01 each of

Vifor Pharma Ltd., St. Gallen, Switzerland

On January 18, 2022, CSL Behring AG (the **Offeror**) published the offer prospectus (the **Offer Prospectus**) for its public tender offer according to articles 125 *et seq.* FMIA (the **Offer**) for all publicly held registered shares of Vifor Pharma Ltd. (**Vifor**) with a nominal value of CHF 0.01 each (each a **Vifor Share**). The offer price for each Vifor Share is USD 179.25 in cash, less the gross amount of any dilutive effects in respect of the Vifor Shares prior to the Settlement (as further described in the Offer Prospectus).

Terms not defined herein have the meaning assigned to them in the Offer Prospectus.

End Result

As of the end of the Additional Acceptance Period on March 22, 2022, 4:00 p.m. Swiss time, the participation of the Offeror and the persons acting in concert with the Offeror is 61,046,902 Vifor Shares in aggregate, corresponding to 93.92% of the issued share capital and voting rights of Vifor (*participation rate*). 60,975,396 Vifor Shares were tendered into the Offer until the end of the Additional Acceptance Period, corresponding to 93.91% of all Vifor Shares to which the Offer relates as of the end of the Additional Acceptance Period (*success rate*).

The following overview summarizes the end result:

	Number of Vifor Shares	In % of share capital/voting rights (participation rate)	In % of Vifor Shares to which the Offer relates (success rate)
Vifor Shares tendered into the Offer	60,975,396	93.81%	93.91%
Vifor Shares held by the Offeror and the persons acting in concert with the Offeror as at the end of the Additional Acceptance Period*	71,506	0.11%	
End result	61,046,902	93.92%	

* Consisting entirely of treasury shares held by Vifor and its subsidiaries. The Offeror and the persons acting in concert with the Offeror (other than Vifor and its subsidiaries) held no Vifor Shares as at the end of the Additional Acceptance Period.

Satisfaction of Offer Conditions

As at the end of the Additional Acceptance Period, the Offer Conditions pursuant to Section B.7(1)(a) (*Minimum Acceptance Rate*) and Section B.7(1)(d) (*No Material Adverse Effect*) of the Offer Prospectus have been satisfied or waived.

The Offer Conditions pursuant to Sections B.7(1)(b), B.7(1)(c), B.7(1)(e), B.7(1)(f), B.7(1)(g), and B.7(1)(h) of the Offer Prospectus remain in effect, as set forth in Section B.7(3) (*Period With Respect to Which the Offer Conditions are in Effect*) of the Offer Prospectus.

Settlement

The Offer and the Settlement are and remain subject to the satisfaction of the Offer Conditions pursuant to Sections B.7(1)(b), B.7(1)(c), B.7(1)(e), B.7(1)(f), B.7(1)(g) and B.7(1)(h) of the Offer Prospectus.

The Offeror declares a Postponement in accordance with Section B.7(3) (*Period With Respect to Which the Offer Conditions are in Effect*) of the Offer Prospectus, and the Settlement is therefore postponed for a period of up to four (4) months after the expiration of the Additional Acceptance Period.

Based on the Offeror's current understanding of the regulatory approval proceedings in different jurisdictions (see Offer Condition pursuant to Sections B.7(1)(b) (*Merger Clearances, Foreign Direct Investment and Other Approvals*) of the Offer Prospectus), and subject to the satisfaction or waiver of the above-mentioned Offer Conditions that remain in effect, the Offeror currently expects the Settlement to occur around mid-2022. The Offeror will announce the Settlement Date after the satisfaction or waiver of all of the above-mentioned Offer Conditions that remain in effect.

The 2022 annual general meeting of shareholders of Vifor, which is convened to resolve, among other things, on the election of Vifor board members necessary to satisfy the Offer Condition pursuant to Section B.7(1)(f) (*Resignation and Appointment of Members of the Board of Directors*) of the Offer Prospectus and on the 2022 Dividend Allowance, is expected to be held on April 26, 2022.

Squeeze-out and Delisting

As described in the Offer Prospectus, the Offeror intends to have Vifor submit an application to SIX Exchange Regulation for the delisting of the Vifor Shares and for an exemption from certain disclosure and publicity obligations until the date of delisting of the Vifor Shares, and to request the cancellation of the remaining publicly held Vifor Shares in accordance with article 137 FMIA or to merge Vifor with the Offeror or another company directly or indirectly controlled by CSL, whereby the remaining public holders of Vifor Shares would be compensated (in cash or otherwise) and not receive any shares in the surviving company if the statutory requirements are met (cf. Section E.3 (*Intentions of Offeror with Respect to Vifor*) and Section K.7 (*Cancellation, Squeeze-out Merger and Delisting*) of the Offer Prospectus).

Offer Restrictions

The Offer is subject to the offer restrictions as set forth in the Offer Prospectus. The Offer Prospectus may be obtained free of charge in German, French and English from Credit Suisse AG

(e-mail: equity.prospectus@credit-suisse.com). The Offer Prospectus and other information concerning the Offer are also available at www.csltransaction.com.

Vifor Pharma Ltd.	Swiss securities number	ISIN	Ticker symbol
Vifor Shares not tendered (first trading line)	36 474 934	CH036 474 934 8	VIFN
Vifor Shares tendered (second trading line)	115 606 016	CH115 606 016 7	VIFNE
Vifor Shares tendered for USD/CHF Conversion Facility (third line, not traded)	115 606 017	CH115 606 017 5	--

March 28, 2022

Lead Financial Advisor

PJT Partners

Financial Advisor
BofA SECURITIES

Financial Advisor
Goldman Sachs

Financial Advisor and Offer Manager

Credit Suisse